Reduced foaming vaccine compositions

Abstract

The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

What is claimed: 
     
         1 . A vaccine composition, comprising:
 at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and   an effective amount of a sugar alcohol foam controlling agent.   
     
     
         2 . The vaccine composition according to  claim 1 , wherein the anhydrous antigenic component is lyophilized or dried. 
     
     
         3 . The vaccine composition according to  claim 1 , wherein the vaccine composition is compressed into a tablet. 
     
     
         4 . The vaccine composition according to  claim 1 , wherein the stabilizer comprises one or more amino acids or salts thereof, protein or salts thereof, albumin, gelatin, or combinations thereof. 
     
     
         5 . The vaccine composition according to  claim 1 , wherein the stabilizer is an amino acid or salts thereof proteins or salts thereof, or combinations thereof. 
     
     
         6 . The vaccine composition according to  claim 1 , wherein the antigenic component is newcastle disease virus, infectious bronchitis virus, fowl pox virus, avian encephalomyelitis virus, marek's disease virus,  Trichophyton verrucosum , avian paramyxovirus,  Mycobacterium paratuberculosis , meleagrid herpesvirus, orf virus, or sheep pox virus. 
     
     
         7 . The vaccine composition according to  claim 1 , further comprising 30% to about 60% by weight of a dissolution agent. 
     
     
         8 . The vaccine composition according to  claim 7 , wherein the dissolution agent is an effervescent agent or pair of effervescent agents. 
     
     
         9 . The vaccine composition according to  claim 7 , wherein the dissolution agent comprises a pair of effervescent agents. 
     
     
         10 . The vaccine composition according to  claim 1 , wherein the effervescent pair comprises a salt and an acid. 
     
     
         11 . The vaccine composition according to  claim 2 , wherein the lyophilized antigenic component comprises greater than 0% to about 90% by weight of the composition. 
     
     
         12 . The vaccine composition according to  claim 1 , wherein the composition is characterized by reduced foaming when in contact with the diluent relative to foaming of a composition that does not include the sugar alcohol. 
     
     
         13 . The vaccine composition according to  claim 12 , wherein foam is reduced by about 50%, the composition that does not include the sugar alcohol 
     
     
         14 . The vaccine composition according to  claim 1 , wherein the sugar alcohol is xylitol, mannitol, sorbitol, or a mixture thereof. 
     
     
         15 . The vaccine composition according to  claim 1 , wherein the antigenic component is a live virus and the composition further comprises neutralizing antibodies against the virus. 
     
     
         16 . A vaccine tablet composition, comprising:
 from greater than 0% to about 90% by weight of at least one lyophilized or dried antigenic component selected from newcastle disease virus, infectious bronchitis virus, fowl pox virus, avian encephalomyelitis virus, marek's disease virus,  Trichophyton verrucosum , avian paramyxovirus,  Mycobacterium paratuberculosis , meleagrid herpesvirus, orf virus, or sheep pox virus, and a stabilizer selected from one or more amino acids or salts thereof, protein or salts thereof, albumin, gelatin, or combinations thereof, susceptible to foaming when the composition is mixed with liquid diluent;   an effective amount of a foam controlling agent selected from xylitol, mannitol, sorbitol, or a mixture thereof; and   30% to about 60% by weight of a dissolution agent.   
     
     
         17 . The vaccine composition according to  claim 16 , wherein the dissolution agent is an effervescent agent or pair of effervescent agents. 
     
     
         18 . The vaccine composition according to  claim 17 , wherein the effervescent pair comprises a salt and an acid. 
     
     
         19 . A method of using a composition, comprising:
 providing a composition according to  claim 1 ; and   administering the composition to a subject.   
     
     
         20 . A method of using a composition, comprising:
 providing a tablet according to  claim 16 ; and   administering the tablet to a subject.